In response to the COVID-19 pandemic, IDCRP researchers activated an observational, longitudinal cohort study (Epidemiology, Immunology and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential [EPICC]) at six military treatment facilities within the United States and are expanding to others.  This study is capturing clinical and laboratory data from patients with confirmed COVID-19, as well as persons under investigation to better understand the natural history of SARS-CoV-2 infection, including the clinical, virologic, and immunologic determinants of severe disease. Findings from this observational study will address numerous gaps in the current understanding of COVID-19 and support the development of treatment and prevention strategies that will not only benefit military personnel, but also civilian populations.   

In addition, IDCRP clinical research sites are participating in a adaptive, randomized-controlled trial to evaluate the efficacy of Remdesivir (ACTT-1) and of Remdesivir + Baricitinib vs. Remdesivir (ACTT-2) among individuals hospitalized with COVID-19, sponsored by the National Institute of Allergy and Infectious Diseases. Preliminary results from the ACTT-1 trial have been published in the New England Journal of Medicine (NEJM).  For more information, please follow the links below.


NEJM Preliminary Results from ACTT-1 

ACTT-1 NCT04280705 

ACTT-2 NCT04401579


IDCRP is committed to reducing the impact of infectious diseases in the military population through collaborative clinical research
Learn More >>